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Urologı́a, Buenos Aires, Argentina, 3 Departamento de Quı́mica Biológica, Facultad de Ciencias Exactas y Naturales,
Universidad de Buenos Aires, Buenos Aires, ArgentinaAlthough natural killer (NK) cells infiltrate clear cell renal cell carcinomas (ccRCC), the most
frequent malignancy of the kidney, tumor progression suggests that they become
dysfunctional. As ccRCC-driven subversion of NK cell effector functions is usually
accompanied by phenotypic changes, analysis of such alterations might lead to the
identification of novel biomarkers and/or targets in immuno-oncology. Consequently, we
performed a phenotypic analysis of peripheral blood NK cells (PBNK) and tumor-infiltrating
NK cells (TINK) from ccRCC patients. Compared to HD, PBNK from ccRCC patients
exhibited features of activated cells as shown by CD25, CD69 and CD62L expression.
They also displayed increased expression of DNAM-1, CD48, CD45, MHC-I, reduced
expression of NKG2D, and higher frequencies of CD85j+ and PD-1+ cells. In addition,
compared to PBNK from ccRCC patients, TINK exhibited higher expression of activation
markers, tissue residency features and decreased expression of the activating receptors
DNAM-1, NKp30, NKp46, NKp80 and CD16, suggesting a more inhibitory phenotype.
Analysis of The Cancer Genome Atlas (TCGA) revealed that CD48, CD45, CD85j and PD-
1 are significantly overexpressed in ccRCC and that their expression is associated with an
NK cell infiltration signature. Calculation of z-scores revealed that their expression on
PBNK, alone or combined, distinguished ccRCC patients from HD. Therefore, these
molecules emerge as novel potential biomarkers and our results suggest that they might
constitute possible targets for immunotherapy in ccRCC patients.
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Renal cell carcinomas (RCC) constitute a malignancy of the kidney
that, according to GLOBOCAN (https://gco.iarc.fr/), exhibited an
incidence of 4.5 cases per 100,000 individuals in 2018. The most
frequent RCC is clear cell RCC (ccRCC, 70-75% of all RCC),
followed by papillary RCC and chromophobe RCC (cancer.gov).
RCC patients diagnosed early have a good prognosis (81% of five-
year survival for stage I tumors and 74% of five-year survival for
stage II tumors). However, patients diagnosed at advanced stages
have a dramatic drop in five-year survival (53% offive-year survival
for stage III tumors and 8% of five-year survival for stage IV
tumors). RCC patients can be treated by partial or radical
nephrectomy or kinase inhibitors. Also, immunotherapy with
checkpoint inhibitors that target the PD-1/PD-L1 axis recently
emerged as a treatment option in advanced disease (1, 2). However,
most of them are diagnosed at later stages and exhibit recurrence
and metastases, without further therapeutic options (3, 4).
Therefore, it is of major interest to discover novel targets for
immunotherapy and to identify biomarkers that might indicate
recurrence or the efficacy of a certain treatment. Eradication of
tumor cells is mainly executed by NK cells and cytotoxic CD8+ T
lymphocytes (CTL) through direct cytotoxicity against tumor cells
and secretion of IFN-g and other proinflammatory cytokines (5, 6).
NK cells recognize specific ligands expressed on tumor cells that
promote the engagement of an array of activating receptors such as
DNAM-1, NKG2D, 2B4, NKG2C, the Natural Cytotoxicity
Receptors (NCR) NKp30, NKp44, NKp46 and NKp80, and
others (5). However, NK cell activation is counterbalanced by the
engagement of an array of inhibitory receptors such as CD85j
(ILT2), KIR, NKG2A, and TIGIT, and NK cell activity is also
regulated by coinhibitory molecules such as PD-1 (5, 7).
Human PBNK comprise 2 major subsets, according to the
expression of CD56 (8). Approximately 90% of PBNK exhibit a
CD3-CD56dim phenotype and a robust cytotoxic activity. The other
5-10% of PBNK display a CD3-CD56bright phenotype, are abundant
in secondary lymph nodes, display poor cytotoxic activity and
mainly produce IFN-g and other cytokines in response to different
stimuli (8–10). Activation of CD56dim NK cells induces several
changes that include the up-regulation of the expression of CD25
and CD69, and the downregulation of the expression of CD62L and
CCR7 (8, 11–13). Moreover, during activation of NK cells,
downregulation of CD62L and CCR7 prevents their egress from
the tissue and migration into lymph nodes, and therefore their
downregulation is considered a feature of tissue residency (8, 11, 12).
In addition, upregulation of CD69, traditionally associated with
activation, has been recently associatedwith tissue residency features
(8, 11–13). Also, acquisition of CD57 expression by humanNK cells
has been associated with terminal differentiation (8, 13–15).
The mechanism of action of NK cells in the control of human
hematologic malignancies is relatively well understood (16, 17).
However, their role in the control of solid tumors is less known.
Although NK cells and CTL infiltrate RCC tumors (18), tumors
manage to grow and metastasize mainly due to the existence of
an immune suppressive tumor microenvironment (TME).
Through local and systemic effects, TME may generate
dysfunctional NK cells with an altered phenotype, and theFrontiers in Immunology | www.frontiersin.org 2detection of such abnormal phenotypic characteristics of
PBNK and TINK may result in the identification of novel
targets for immunotherapy and/or biomarkers.
It was observed that TINK from ccRCC patients exhibit a
diverse expression of KIR, CD85j and NKG2A (19), and that the
extent of NK cell infiltration and the expression of CD16 and
lytic mediators is associated with the functional capacity of these
TINK (19, 20). Reduced expression of NKp46 was also described
in TINK from ccRCC patients (21). Also, it has been observed
that a lower frequency of TINK express the activating receptors
NKp46, NKG2D, NKG2C, and a higher frequency of TINK
express the inhibitory receptors NKG2A, CD158a and CD158b
(22). Moreover, TINK from ccRCC display impaired
degranulation (21, 22) and cytokine production (22). Others
also described an abnormal phenotype of PBNK in RCC patients
(84% of which were ccRCC) such as an increased expression of
PD-1 that correlated with disease stage and was significantly
reduced after surgical removal of the tumor (23). Phenotypic
alterations of NK cells might be different in PBNK compared to
TINK because TINK establish a close interaction with the TME
while PBNK are only exposed to systemic effects of the TME.
However, the comparative characteristics of PBNK and TINK
from ccRCC remain mostly ill-defined. Such studies may unravel
phenotypic alterations of NK cells that may represent useful
prognostic, therapeutic and follow-up biomarkers and/or lead to
the discovery of new candidates for immunotherapy, especially
considering that immunotherapies aimed at reinvigorating NK
cells in RCC constitute promising approaches (24).
Therefore, the aim of this work was to perform a phenotypic
analysis of previously poorly explored markers expressed by
PBNK and TINK from ccRCC patients to elucidate if systemic
and local effects affect these cells critically involved in the
elimination of tumor cells. We complemented these studies
with bioinformatic analyses of TCGA data to establish whether
the overexpression of inhibitory receptors detected in this work
on NK cells from ccRCC patients is a general characteristic of
ccRCC tumor samples and is associated with a NK cell signature.MATERIALS AND METHODS
Patients and Samples
Peripheral blood mononuclear cells (PBMC) were isolated from
blood of healthy donors (HD, provided by the Blood Bank of the
Hospital Churruca-Visca of Buenos Aires) or kidney cancer
patients (drawn just before nephrectomy) by Ficoll-Paque™ Plus
(GE Life Sciences) centrifugation. Blood and nephrectomies were
provided by the urology service from the Centro de Educación
Médica e Investigaciones Clıńicas “Norberto Quirno” (CEMIC)
from the city of Buenos Aires. The characteristics of the patients are
listed in Table 1. A total of 12 patients with ccRCC and 13 HDwere
included in the study. This study was conducted according to the
guidelines of the Declaration of Helsinki, and approved by the
Institutional Ethics Committee of IBYME (protocol CE003-03/
2014, date of approval: March 20, 2014). Also, informed consent
was obtained from all subjects involved in the study.June 2021 | Volume 12 | Article 681615
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Surgical biopsies of human RCC were obtained from patients
subjected to partial or radical nephrectomy and used for the
preparation of single cell suspensions. Briefly, tumors were cut
into small pieces and subjected to mechanical dissociation and
filtration through nylon mesh (0.45 µm) in the presence of
phosphate-buffered saline. After washing with saline solution,
immune cells were enriched by Ficoll-Paque™ Plus (GE Life
Sciences) centrifugation. All procedures were performed on ice.
Diagnosis of each RCC was confirmed by the pathology service
and only data corresponding to ccRCC were presented in
this study.
Antibodies and Reagents
The following mAb were used for flow cytometry (FC): APC
anti-CD56 (N901) from Beckman Coulter; PE/Cy7 anti-CD3
(UCHT1) from TONBO; FITC anti-DNAM-1 (DX11) from BD;
FITC anti-CD85j (292305), AlexaFluor488 anti-TRAIL (71908),
PE anti-NKG2A (131411) and AlexaFluor488 anti-NKG2C
(134591) from Biotechne; FITC anti-CD16 (3G8); FITC anti-
CD69 (FN50); PE anti-CD25 (BC96); PE anti-CD62L (DREG-
56); PE anti-NKG2D (1D11), PE anti-NKp30 (P30-15); PE
anti-NKp46 (9E2); PE anti-NKp80 (5D12); PE anti-2B4 (C1.7);
FITC anti-CD48 (BJ40); APC/Cy7 anti-CD45 (HI30);
AlexaFluor488 anti-PD-1 (29E.2A3); FITC anti-HLA class I (W6/
32); PE anti-FasL (NOK-1); PEanti-NKp44 (9E2); FITCanti-CD57
(HCD57); FITCanti-CCR7(G043H7); FITCanti-CD27 (M-T271);
and PE anti-TIGIT (A15153G) from Biolegend.
Flow Cytometry
FC was performed as described (25, 26). Non-specific staining
was blocked with 10% normal mouse serum. Cells were analyzed
in a FACSCanto II flow cytometer (BD). Data were analyzed
using FlowJo X software (BD) and results were expressed as
geometric mean fluorescence intensity (MFI), as relative MFI
(rMFI) calculated as the MFI of the specific mAb divided by the
MFI of the “fluorescence minus one” (FMO) control or as
percentage of positive cells. For comparison of PBNK with
TINK, we used rMFI because the FMO of the tumor samples
was higher than the FMO of the blood samples.Frontiers in Immunology | www.frontiersin.org 3Bioinformatic Analysis
The Tumor IMmune Estimation Resource (TIMER, http://timer.
cistrome.org/) (27) and the Gene Expression Profiling Interactive
Analysis 2 (GEPIA2, http://gepia2.cancer-pku.cn/) (28)were used to
analyze publicly available RNAseq data from The Cancer Genome
Atlas (TCGA). TIMER was used to study the differential expression
between ccRCC tumor and adjacent normal tissues datasets for the
different genes of interest, and the statistical significance was
computed by differential analysis (edgeR). GEPIA2 was used for
correlation analysis between a multi-gene NK cell signature (NCR1,
XCL2, IL2RB, KLRF1, KIR2DL4, KLRC3, XCL1, NKG7, CTSW,
NCR3 and IL18RAP) and the genes of interest (29, 30).
Statistical Analysis
Principal component analysis (PCA) of scaled data was conducted
in R (version 4.0.3) (31) with missMDA (32) to compute missing
values. For the comparison of PBNK from HD with PBNK from
ccRCC patients (Figure 1A), the MFI of CD56, CD62L, CCR7,
CD16, CD25, CD69, FasL, TRAIL, CD48, CD27, CD45, MHC-I,
PD-1, DNAM-1, NKG2D, NKp30, NKp44, NKp46, NKp80,
NKG2C, 2B4, NKG2A, and TIGIT on CD56bright and CD56dim
NK cells, and the MFI of CD85j and CD57 on CD56dim cells were
used. For the comparison of PBNK with TINK from ccRCC
patients (Figure 3A), the rMFI of the following markers were
used: CD62L, CCR7, CD16, CD25, CD69, FasL, TRAIL, CD48,
CD27, CD57, MHC-I, PD-1, DNAM-1, NKG2D, NKp30, NKp44,
NKp46, NKp80, NKG2C, 2B4, NKG2A, TIGIT, and CD85j. Plots
were generated using the package factoextra (33). z-scores for
CD85j, CD45 and CD48 expression were calculated using the
formula z=(x-µ)/s, where z is the “z-score”, x is the MFI of CD45
expression or the frequency of CD85j+ or CD48+ from total PBNK
in each individual sample, µ is the mean of the MFI of CD45
expression or the mean of the frequency of CD85j+ or CD48+
PBNK cells in the HD population, and s is the standard deviation
of each set of these data in the HD population. The sum of z-scores
was calculated for patients for whom data were available for each
parameter (receptors). To compare PBNK from HD with PBNK
from ccRCC patients, a two-sided unpaired t-test with Welch´s
correction (when samples passed the normality test) or with
Mann-Whitney´s correction (when samples did not pass the
normality test) was used. To compare PBNK with TINK from
ccRCC patients, a two-sided paired t-test was used when samples
passed the normality test, and a two-sided paired t-test with
Wilcoxon rank test was used when samples did not pass the
normality test. D´Agostino-Pearson was used as normality test.
Data were analyzed using Prism 6.0 software (GraphPad).RESULTS
PBNK From ccRCC Patients Exhibit an
Activated Phenotype With an Altered
Balance of Activating and Inhibitory
Receptors
First, we phenotyped PBNK from ccRCC patients and HD (the
characteristics of the patients are detailed in Table 1). NK cellsTABLE 1 | Patients with ccRCC included in the study.
Patient Gender Age Stage Type of nephrectomy*
1 M 74 Fuhrman II P
2 M 74 Fuhrman II R
3 M 67 Furhman II (pT3bpN0) R
4 M 61 Fuhrman II P
5 M 63 Fuhrman II P
6 M 67 Fuhrman II/III R
7 F 59 Fuhrman II R
8 M 59 Fuhrman II R
9 M 74 Fuhrman II P
10 M 73 Fuhrman IV R
11 M 71 Fuhrman II R
12 F 72 Fuhrman II P*P, partial; R, radical.June 2021 | Volume 12 | Article 681615
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FIGURE 1 | Cell surface markers differentiate ccRCC patients from HD and indicate that PBNK from ccRCC patients exhibit an activated phenotype. MFI of the
molecules analyzed on CD3-CD56bright and CD3-CD56dim cells of HD and ccRCC PBNK were used to perform a PCA (A). The graph of individuals with the
confidence ellipse is shown. Also, PBNK cells from healthy donors (HD) and ccRCC patients (P) were analyzed by FC to compare the intensity of expression of CD56
on CD3-CD56bright (B) and on CD3-CD56dim NK cells (C), the frequencies of CD25+ cells in CD3-CD56bright (D) and in CD3-CD56dim NK cells (E), the intensity of
expression of CD25 on CD3-CD56bright (F) and on CD3-CD56dim NK cells (G), the frequencies of CD69+ cells in CD3-CD56bright (H) and in CD3-CD56dim NK cells (I),
the intensity of expression of CD69 on CD3-CD56bright (J) and on CD3-CD56dim NK cells (K), the frequencies of CD62L+ cells in CD3-CD56bright (L) and in CD3-
CD56dim NK cells (M), and the intensity of expression of CD62L on CD3-CD56bright (N) and on CD3-CD56dim NK cells (O). For HD: n=11 (B), n=12 (C); n=13 (D–G);
n=9 (H–K) and n=10 (L–O). For P: n=12 (B–G), n=11 (H–K), and n=10 (L–O). A two-sided unpaired t-test with Welch’s correction was used in (B–D, F–I, K–O). A
two-sided unpaired t-test with Mann-Whitney´s correction was used in (E, J). ns, not significant; *p < 0.05; **p < 0.01; ***p < 0.001.Frontiers in Immunology | www.frontiersin.org June 2021 | Volume 12 | Article 6816154
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further characterized as CD3-CD56bright and CD3-CD56dim cells
using the gating strategy described in Supplementary Figure 1.
A PCA of cell surface markers used to analyze NK cells
phenotype demonstrated that, according to PC1 and PC2,
PBNK from ccRCC patients segregated together and separated
from HD (Figure 1A). Therefore, as PBNK from ccRCC patients
and HD could be discriminated with these markers, we explored
the expression of these receptors and molecules in more detail.
Compared to HD, ccRCC patients exhibited similar
frequencies of PBNK and distribution of CD3-CD56bright and
CD3-CD56dim cells (not shown) but with lower amounts of CD56
expression in both NK cell subsets (Figures 1B, C). Moreover,
CD3-CD56bright but not CD3-CD56dim cells from ccRCC patients
showed a significant increased frequency of CD25+ cells
(Figures 1D, E) and they expressed significantly higher
amounts of CD25 (Figures 1F, G). In addition, only CD3-
CD56dim cells but not CD3-CD56bright cells from ccRCC
patients displayed a significant increased frequency of CD69+
cells (Figures 1H, I), and both subsets from ccRCC patients
expressed significantly higher amounts of CD69 (Figures 1J, K).
Moreover, CD3-CD56bright and CD3-CD56dim NK cells from
ccRCC patients presented a lower frequency of CD62L+ cells, a
finding that was most notorious in CD3-CD56dim cells
(Figures 1L, M) and was accompanied by significantly lower
expression of CD62L only on CD3-CD56dim NK cells
(Figures 1N, O). Also, we did not observe differences in the
expression of CCR7, CD27 and CD57 on either subpopulation of
PBNK from ccRCC patients compared to HD (not shown).
Overall, our results show that PBNK from RCC patients
display features of activated NK cells.
Next, we analyzed the expression of a set of activating and
inhibitory receptors that regulate NK cell activity in CD3-
CD56bright and CD3-CD56dim NK cells from ccRCC patients
compared to HD. Among the activating receptors analyzed, we
observed that there were no differences in the frequency of
CD16+ NK cells (Figure 2A). However, we observed an
increased expression of DNAM-1 (Figure 2B), a reduced
expression of NKG2D (Figure 2C), and no changes in the
expression of NKp30 (Figure 2D), NKp46 (Figure 2E), NKp80
(Figure 2F), NKG2C (not shown), 2B4 (not shown) and NKp44
(not shown) in both subsets of PBNK. We also detected a higher
frequency of NK cells that expressed the 2B4 ligand CD48
(Figure 2G) in the CD3-CD56bright and CD3-CD56dim NK cell
subsets from ccRCC patients compared to HD. Both subsets of
PBNK from ccRCC also exhibited increased amounts of CD48
(Figure 2H). In addition, among the inhibitory receptors and
other molecules involved in negative signaling, we did not
observe differences in the expression of NKG2A and TIGIT in
CD3-CD56bright and CD3-CD56dim NK cells from ccRCC
patients compared to HD (not shown). Also, we observed that
CD3-CD56bright did not express CD85j (not shown) but that
CD3-CD56dim cells from ccRCC patients exhibited higher
frequencies of CD85j+ cells but with similar amounts of
expression compared to HD (Figure 2I). In addition, CD3-
CD56bright and CD3-CD56dim NK cells from ccRCC patientsFrontiers in Immunology | www.frontiersin.org 5exhibited a substantially higher expression of CD45 (Figure 2J),
while only CD3-CD56dim PBNK cells from ccRCC patients
presented a higher frequency of PD-1+ cells (Figure 2K)
without changes in the amount of PD-1 expression (not
shown). We also observed that CD3-CD56bright and CD3-
CD56dim NK cells from ccRCC patients displayed higher
expression of MHC-I (Figure 2L).
In addition, we did not observe differences in the frequency
and amounts of expression of molecules involved in the cytotoxic
function of NK cells via the death receptor pathway, such as FasL
and TRAIL, in both subsets of PBNK from ccRCC patients
compared to HD (not shown).
In summary, compared to HD, PBNK from ccRCC patients
exhibit features of activated NK cells with a dysbalanced array of
activating and inhibitory cell surface receptors skewed towards
an inhibitory phenotype.TINK Exhibit Activated and Tissue
Residency Characteristics With a Balance
of Activating and Inhibitory Receptors
Even More Markedly Skewed Towards an
Inhibitory Phenotype
To analyze the features of TINK and considering that CD56bright
and CD56dim NK cell subsets could not be assessed separately
within the tumor, we used the gating strategy described in
Supplementary Figure 2. A PCA of the same cell surface
markers used to analyze PBNK demonstrated that, according
to PC1 and PC2, PBNK from ccRCC patients could be
differentiated from TINK (Figure 3A). Hence, as with PBNK,
we explored these differences in more detail.
Compared to PBNK from paired ccRCC patients, TINK
exhibited similar amounts of expression of CD56 (not shown),
and a higher frequency of CD25+ (Figure 3B) with similar
expression of CD25 (Figure 3C). TINK also displayed a higher
frequency of CD69+ cells (Figure 3D) and expressed higher
amounts of CD69 (Figure 3E). In addition, they showed a lower
frequency of CD62L+ cells (Figure 3F) and expressed less CD62L
(Figure 3G) than PBNK. Also, we did not find differences in the
expression of CCR7, CD27 and CD57 (not shown). Thus, TINK
from ccRCC patients also display features of activated NK cells
with tissue residency characteristics.
The analysis of the expression of activating receptors revealed
that TINK, compared to PBNK from ccRCC patients, exhibited a
reduced frequency of CD16+ cells (Figure 4A) and expressed less
CD16 (Figure 4B). Similarly, TINK presented a reduced
frequency of DNAM-1+ cells (Figure 4C) and expressed less
DNAM-1 (Figure 4D). TINK also exhibited reduced expression
of NKp30 (Figure 4E), NKp46 (Figure 4F) and NKp80
(Figure 4G), but similar expression of NKG2D (Figure 4H)
and frequencies and intensity of expression of NKp44 and
NKG2C (not shown). Also, we did not observe differences in
the frequency of CD48+ NK cells (Figure 4I) or in the expression
of CD48 (Figure 4J). In addition, the analysis of the expression
of some inhibitory receptors demonstrated that there were no
differences in the frequency of CD85j+ (Figure 4K), NKG2A+June 2021 | Volume 12 | Article 681615
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molecules (not shown) or CD45 (Figure 4L) expressed by PBNK
and TINK. Furthermore, there was a trend towards a higher
frequency of PD-1+ cells in TINK compared to PBNK that did
not reach statistical significance (Figure 4M), while the amount
of expression of MHC-I (Figure 4N) was similar in both NK
cell compartments.
In addition, we observed no changes in the frequency of FasL+
and TRAIL+ TINK and in the intensity of expression of FasL and
TRAIL compared to PBNK (not shown).
In summary, TINK exhibit features of activated NK cells with
tissue residency characteristics and a pattern of activating andFrontiers in Immunology | www.frontiersin.org 6inhibitory receptors that is skewed towards an even more
inhibitory phenotype than PBNK from ccRCC patients.Bioinformatic Analyses Confirm That
Overexpression of CD85j, CD45, CD48 and
PD-1 in TINK Is Associated With a NK Cell
Tumor Infiltration Signature in ccRCC
To interrogate whether the abnormal expression of NK cell
receptors observed in our study is a general feature of patients
with ccRCC, we performed a bioinformatic analysis using the





FIGURE 2 | PBNK from ccRCC patients exhibit an altered phenotype characterized by a dysregulation in the expression of activating and inhibitory receptors.
PBNK cells from healthy donors (HD) and ccRCC patients (P) were analyzed by FC to compare, in the CD3-CD56bright (left graph) and CD3-CD56dim cells (right
graph) subsets, the frequency of cells that expressed CD16 (A), the intensity of expression of DNAM-1 (B), NKG2D (C), NKp30 (D), NKp46 (E), NKp80 (F), the
frequency of cells that expressed CD48 (G), and the intensity of expression of CD48 (H). Also, we analyzed the frequency of CD85j+ cells (left graph) and the
intensity of expression of CD85j (right graph) in CD3-CD56dim cells (I). In addition, in CD3-CD56bright (left graph) and CD3-CD56dim cells (right graph) we analyzed the
intensity of expression of CD45 (J), the frequency of PD-1+ cells (K), and the intensity of expression of MHC-I (L). For HD: n=13 (A–F, J), n=11 (G, H), n=10 (I, L)
and n=6 (K). For P: n=12 (A–C, E, J), n=1 (D, F, I), n=9 (G, H), n=5 (K) and n=6 (L). A two-sided unpaired t-test with Welch´s correction was used in left graphs of
(A–C, G, H), in both graphs of (D–F), and in right graph of (I) A two-sided unpaired t-test with Mann-Whitney´s correction was used in right graphs of (A–C, G, H), in
left graph of (I) and in both graphs of (J–L). ns, not significant; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.June 2021 | Volume 12 | Article 681615
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a) were encoded by genes that exhibited altered expression in
ccRCC compared to healthy kidney, and b) were associated with
a NK cell infiltration signature in ccRCC samples. This signature
was established by the overexpression of a group of 11 NK cell-
associated genes that are not expressed or are weakly expressed
on CD8+ T cells: NCR1, XCL2, IL2RB, KLRF1, KIR2DL4, KLRC3,
XCL1, NKG7, CTSW, NCR3, and IL18RAP. We observed that
CD85j (Figure 5A), CD45 (Figure 5B), CD48 (Figure 5C) and
PD-1 (Figure 5D) were significantly overexpressed in ccRCC.Frontiers in Immunology | www.frontiersin.org 7Moreover, expression of CD85j (Figure 5E), CD45 (Figure 5F),
CD48 (Figure 5G) and PD-1 (Figure 5H) were strongly
associated with a NK cell infiltration signature. Therefore, our
results suggest that higher expression of CD45 on NK cells,
increased frequencies of CD85j+ and higher expression and
frequency of CD48+ NK cells (as detected by multicolor FC)
might be a common characteristic of patients with ccRCC.
Moreover, as their expression distinguishes ccRCC patients





FIGURE 3 | Cell surface markers differentiate TINK from PBNK in ccRCC and indicate that TINK from ccRCC patients exhibit an activated phenotype. rMFI of the
molecules analyzed on CD3-CD56+ cells from PBNK and TINK from ccRCC patients were used to perform PCA (A). The graph of individuals with the confidence ellipse
is shown. Also, PBNK and TINK from ccRCC patients were analyzed by FC to compare the frequency of CD25+ cells (B), the intensity of expression of CD25 (C), the
frequency of CD69+ cells (D), the intensity of expression of CD69 (E), the frequency of CD62L+ cells (F), and the intensity of expression of CD62L (G). In (C, E, G),
relative MFI (rMFI) was used instead of MFI because the FMO was different for PBNK and TINK. n=9 (B, C); n=8 (D, E); n=6 (F, G). A two-sided paired t-test was used
in (B, D) A two-sided paired t-test with Wilcoxon rank test was used in (C, E–G). ns, not significant; *p < 0.05; **p < 0.01; ***p < 0.001.June 2021 | Volume 12 | Article 681615
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and CD48 Unravel Their Potential Use
as Biomarkers
To explore if these inhibitory receptors could be part of a
signature that might be used as biomarkers, we normalized our
results calculating the z-scores for CD85j, CD45 and CD48, and
we also combined these z-scores to explore if the behavior of
PBNK from ccRCC differs from HD. We observed that z-scores
from CD85j (Figure 6A), CD45 (Figure 6B) and CD48
(Figure 6C) in PBNK were significantly higher in ccRCC
patients than in HD. Furthermore, the sum of z-scores by pairs
of receptors improved the discrimination power between ccRCC
patients and HD (Figures 6D–F). However, the most remarkable
discrimination power was achieved with the sum of z-scores
from the three receptors, as the mean for ccRCC patients was 9.5Frontiers in Immunology | www.frontiersin.org 8standard deviations above the mean of HD and every single
patient’s value was at least 5 standard deviations above the mean
of the HD (Figure 6G).
In summary, besides PD-1, which is an already known target
for immunotherapy, our results suggest that expression of
CD85j, CD45 and CD48 on NK cells from ccRCC patients
constitute potential biomarkers and they might constitute
candidates for therapeutic intervention that deserve
further investigation.DISCUSSION
Most patients with advanced ccRCC experience tumor
recurrence and metastases (34). Notably, ccRCC is a tumorA B D E
F G IH J
K L M N
C
FIGURE 4 | TINK from ccRCC patients exhibit a similar increased expression of inhibitory receptors than PBNK and additional decreased expression of activating
receptors. Peripheral blood NK cells (PBNK) and tumor-infiltrating NK cells (TINK) from ccRCC patients were analyzed by FC to compare the frequency of CD16+
cells (A), the intensity of expression of CD16 (B), the frequency of DNAM-1+ cells (C), the intensity of expression of DNAM-1 (D), the intensities of expression of
NKp30 (E), NKp46 (F), NKp80 (G) and NKG2D (H), the frequency of CD48+ cells (I), the intensity of expression of CD48 (J), the frequency of CD85j+ cells (K), the
intensity of expression of CD45 (L), the frequency of PD-1+ cells (M) and the intensity of expression of MHC-I (N). In (B, D–H, J, N), the relative MFI (rMFI) was used
instead of MFI because the FMO was different for PBNK and TINK. n=9 (A–D, F, H, L); n=8 (E, G, I–K); n=3 (M); n=4 (N). A two-sided paired t-test was used in
(A, D, E, G–I) and (K) A two-sided paired t-test with Wilcoxon rank test was used in (B, C, F, J, L, N). ns, not significant; *p < 0.05; **p < 0.01; ***p < 0.001.June 2021 | Volume 12 | Article 681615
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FIGURE 5 | TCGA analyses shows that CD85j, CD45, CD48 and PD-1 are overexpressed in ccRCC and associated with a NK cell signature. Analysis of expression
of CD85j (A), CD45 (B), CD48 (C) and PD-1 (D) in ccRCC (n=533) compared to normal kidney (n=72) using the TIMER platform with data deposited in the TCGA.
Also, a correlation analysis between the expression of CD85j (E), CD45 (F), CD48 (G) and PD-1 (H) and a NK cell signature (established by the overexpression of a
group of 11 NK cell-associated genes that are not expressed or are weakly expressed on CD8+ T cells: NCR1, XCL2, IL2RB, KLRF1, KIR2DL4, KLRC3, XCL1,
NKG7, CTSW, NCR3, and IL18RAP) in ccRCC was performed using the GEPIA2 platform. ***p < 0.001.A B
D E F G
C
FIGURE 6 | Normalization of the expression of CD85j, CD45 and CD48 on NK cells significantly discriminates between ccRCC and HD samples. Normalization of
the expression of CD85j, CD45 and CD48 in PBNK was performed calculating the respective z-scores and individual z-scores for CD85j (A), CD45 (B) and CD48
(C) were depicted. Also, the sum of z-scores was calculated for the pairs of receptors CD85j and CD45 (D), CD85j and CD48 (E), and CD45 and CD48 (F) as well
as the sum of z-scores of CD85j, CD45 and CD48 (G). The dashed line in each graph indicates the value of the mean plus 3 SD. For HD: n=10 (A), n=12 (B), n=11
(C, F), n=9 (D) and n=8 (E, G). For P: n=10 (A, D), n=12 (B) and n=9 (C, E–G). *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.Frontiers in Immunology | www.frontiersin.org June 2021 | Volume 12 | Article 6816159
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this finding might explain tumor progression even in the
presence of high NK cell and CD8 T cell infiltration (36).
However, patients with RCC treated with anti-PD-1 or anti-
PD-L1 mAb respond relatively well and exhibit a higher
objective response than the mean trend (37). Therefore, an
immunosuppressive TME plays an important role in the
generation of dysfunctional cytotoxic cells. Importantly, even
though the administration of the immunological checkpoint
inhibitors nivolumab and ipilimumab, alone or combined with
other therapies, opened new therapeutic opportunities (38), most
of the patients still do not benefit from these treatments.
Therefore, the identification and validation of novel targets in
immuno-oncology that, alone or combined with PD-1 blockade,
may reinvigorate the function of cytotoxic cells becomes crucial
but constitutes a formidable challenge. Bioinformatic analysis
based mainly on RNA expression in whole tumor samples does
not allow for discrimination of the different cells that constitute
the TME. Additionally, such analysis does not account for post-
translational modifications that may impact on cell surface
expression of candidate molecules. Therefore, the analysis of
the coding RNA may not mirror the protein expression.
Consequently, the analysis of peripheral blood cells and paired
tumor-infiltrating cells becomes a valuable tool in the path of
identification and validation of novel predictive biomarkers and
targets in immuno-oncology (39).
Given the relevant role of NK cells during tumor immunity
and the promising pipelines in the field of NK cell therapies (40),
we performed an exhaustive phenotypic analysis of NK cells
from ccRCC patients with the aim to select candidates for further
investigation of their potential use as biomarkers and/or targets
for immunotherapy.
Interestingly, the panel of markers used in this work enabled
us to discriminate ccRCC PBNK from HD, as shown by PCA. A
more detailed analysis of the differences between HD and ccRCC
PBNK phenotype revealed that compared to HD, PBNK from
ccRCC patients exhibited features of activated NK cells shown by
the increased frequency and expression of CD25 and CD69, and
a decreased expression of CD62L (8, 41, 42). These PBNK did
not exhibit alteration in their maturation or terminal
differentiation status (according to the expression of CD27 and
CD57, respectively) but displayed an abnormal array of
activating and inhibitory receptors. The most notable change
in the activating receptors was the decreased expression of
NKG2D on PBNK from ccRCC patients. NKG2D is critical for
tumor elimination (43, 44) and its down-regulation may arise as
a consequence of the presence of soluble ligands such as MICA in
plasma of cancer patients, a fact that contributes to tumor
progression and immune escape (45, 46). Also, although there
were no differences in the expression of the activating receptor
2B4, PBNK from ccRCC patients displayed increased frequencies
and expression of its ligand CD48 (47). Notably, cis interaction
between 2B4 and CD48 on NK cells has been reported to reduce
the availability of 2B4 to interact with CD48 in trans on tumor
cells, resulting in a heightened NK cell activation threshold (48).
In addition, under certain circumstances 2B4-CD48 engagementFrontiers in Immunology | www.frontiersin.org 10leads to functional inhibition of NK cells (49). Moreover, CD48
can also bind to CD2 and this interaction and the effect of CD48
engagement on the cells that express it has not been properly
studied yet. Therefore, up-regulation of CD48 on PBNK from
ccRCC may contribute to tumor resistance to NK cell-mediated
effector functions.
Other remarkable changes in PBNK from ccRCC patients
were the increased frequencies of CD3-CD56dim cells that
expressed the inhibitory receptor CD85j and the coinhibitory
molecule PD-1, and the expression of higher amounts of CD45
and MHC-I on both subsets of NK cells. CD85j engagement on
NK cells limits their effector functions (26, 50) and its up-
regulation in PBNK from triple negative breast cancer patients
has been associated with impaired antibody-dependent cell-
mediated cytotoxicity (ADCC) elicited by Cetuximab (51).
HLA-G, which binds to CD85j with higher affinity than the
classical MHC-I (35), is expressed in RCC cells (36, 37) and plays
an inhibitory role on NK cell-mediated cytotoxicity against
tumor cells (37). CD45 is a receptor with tyrosine phosphatase
activity that participates in fine-tuning of cellular responses (52–
54). Its phosphatase activity negatively controls the activation
threshold of different cells from the immune system to diverse
stimuli and alteration in such signaling has been involved in
different pathological conditions. Regarding the upregulation of
MHC-I observed on NK cells, such effect also may contribute to
their inhibition as it was shown that cross-linking of MHC-I
molecules on human NK cells inhibits their function (55, 56),
while protecting them from self-killing (fratricide) through
engagement of 2B4 (57). MHC-I expression on tumors cells
might also play an important role in preventing NK cells
activation through engagement of inhibitory receptors.
Therefore, PBNK from ccRCC patients, besides exhibiting an
activated status exhibited a phenotype skewed towards inhibition
or higher activation threshold and could be clearly distinguished
from PBNK from HD with the surface molecules analyzed in
this work.
Moreover, performing a PCA we also demonstrated that
PBNK from ccRCC patients differ from TINK. A more detailed
phenotypic analysis revealed that TINK also exhibited an
activated phenotype with tissue residency features
characterized by a higher frequency of CD25+ and of CD69+
cells, higher expression of this last molecule, lower frequency of
CD62L+ and DNAM-1+ cells and lower expression of both
molecules. Also, TINK did not exhibit alteration in their
maturation or terminal differentiation status but exhibited a
reduced frequency of CD16+ cells and diminished expression
of CD16, NKp30, NKp46 and NKp80, but conserved the reduced
expression of NKG2D detected in PBNK. Such phenotype may
not only impair direct tumor recognition by TINK through
many activating receptors but also may weaken their ability to
trigger ADCC through CD16. Regarding inhibitory receptors,
TINK maintained the increased frequency of CD85j+ and CD48+
cells observed in PBNK from ccRCC patients. Moreover, each of
the 3 patients analyzed for PD-1 expression exhibited increased
frequency of PD-1+ cells in TINK compared to PBNK, but such
increase was not significant likely due to the low number ofJune 2021 | Volume 12 | Article 681615
Ziblat et al. NK Cells in Kidney Cancersamples analyzed. TINK also exhibited similar heightened
expression of CD45 and MHC-I as PBNK from ccRCC.
Overall, our results indicate that TINK exhibit an activated
phenotype with tissue residency characteristics that is even
more skewed towards inhibition than PBNK from ccRCC
patients. Coopting regulatory circuits that result in the
upregulation of inhibitory receptors such as CD85j, CD45,
CD48 and PD-1 may raise NK cell activation threshold,
resulting in hyporesponsive NK cells. Such tumor-driven
subversion of NK cells may impose restrictions to their effector
functions to control tumor progression and metastases. In
addition, within the TME, a concomitant downregulation of
activating receptors also would desensitize NK cells to tumor
cells that express the specific ligand, further facilitating
tumor progression.
In addition, a bioinformatic analysis revealed that, compared
to healthy kidneys, increased expression of CD85j, CD45, CD48
and PD-1 is a general characteristic of ccRCC and is strongly
associated with an NK cell tumor infiltration signature in this
type of tumor. Thus, besides the well-known role of PD-1
blockade on cytotoxic CD8+ T cells, our results suggest that
NK cells might also be involved in the efficacy of anti-PD-1/PD-
L1 immunotherapy in ccRCC. Also, CD85j, CD45 and CD48
emerge as novel potential targets whose inhibition or blockade
should be further examined as it may promote the reinvigoration
of TINK. In addition, to evaluate the potential of these molecules
as a signature capable of differentiating patients and HD, we
calculated z-scores for each receptor and used them alone or
combined. Remarkably, the sum of z-scores for CD85j, CD45
and CD48 exhibited a strong discrimination ability between
ccRCC and HD samples. Therefore, we postulate their
potential utility as peripheral biomarkers in ccRCC.
In summary, PBNK from ccRCC patients display an
inhibitory profile characterized by overexpression of CD85j,
CD45, CD48 and PD-1, while TINK exhibit additional
alterations characterized by a decreased expression of several
activating receptors. Therefore, our results suggest that CD85j,
CD45 and CD48 expression represent interesting potential
biomarkers in ccRCC and they might constitute possible
candidates for immunotherapy whose blockade may result in
their validation as novel targets in immuno-oncology.DATA AVAILABILITY STATEMENT
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